Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine

Fujimori, Juichi; Miyazawa, Kouichi; Nakashima, Ichiro

doi:10.1016/j.jneuroim.2021.577755

Cited by 23 publications

(18 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apart from evidence that the yellow fever vaccine may be associated with relapses, other vaccine data does not support an association between vaccination and MS relapse risk ( Zrzavy et al, 2019 ; Mailand and Frederiksen, 2017 ). There have been four cases of new MS diagnoses following mRNA COVID-19 vaccine administration, but MRI studies, in those cases demonstrated a mix of old and new lesions, which prompted the authors to conclude there likely was clinically latent disease prior to vaccination itself ( Khayat-Khoei et al, 2021 ; Havla et al, 2021 ; Fujimori et al, 2021 ). Both Pfizer-BioNTech and Moderna vaccines against COVID-19 are highly effective mRNA vaccines approved by FDA ( Banerji et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

“…Multiple sclerosis (MS) with onset in the setting of acute SARS-CoV-2 virus infection has been described ( Moore et al, 2021 ; Palao et al, 2020 ; Yavari et al, 2020 ). Cases of MS reactivation following non-mRNA COVID-19 vaccinations have been reported ( Voysey et al, 2021 ; Khayat-Khoei et al, 2021 ), but so far only four reports of MS onset following vaccination with the mRNA COVID-19 vaccine have been published ( Khayat-Khoei et al, 2021 ; Havla et al, 2021 ; Fujimori et al, 2021 ). Here, we report five cases of onset of MS in the setting of recent mRNA COVID-19 vaccine administration.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure

Toljan

Amin

Kunchok

et al. 2022

Journal of Neuroimmunology

View full text Add to dashboard Cite

Background Multiple sclerosis (MS) with onset in the setting of acute SARS-CoV-2 virus infection has been reported, and reactivation of MS following non-mRNA COVID-19 vaccination has been noted, but there have only been three reports of newly diagnosed MS following exposure to mRNA COVID-19 vaccine. The association cannot be determined to be causal, as latent central nervous system demyelinating disease may unmask itself in the setting of an infection or a systemic inflammatory response. We report a series of 5 cases of newly diagnosed MS following recent exposure to mRNA COVID-19 vaccines. Latency from vaccination to initial presentation varied. Neurological manifestations and clinical course appeared to be typical for MS including response to high dose steroids in 4 cases and additional need for plasmapheresis in one case. Conclusion Acute neurological deficits in the setting of recent mRNA COVID-19 vaccine administration may represent new onset multiple sclerosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure

Toljan

Amin

Kunchok

et al. 2022

Journal of Neuroimmunology

View full text Add to dashboard Cite

show abstract

“…In these cohorts, both first and second doses of either vaccine led to transient reactions typical of healthy individuals, such as fatigue, headache, and fever (FBS and Schmidt, 2021;. Though noted in several case reports, disease relapse is also believed to be a rare occurrence in MS patients following vaccination (Etemadifar et al, 2021;Fujimori et al, 2021;Havla et al, 2022). An Israeli observational study independently confirmed these suspicions, demonstrating through its findings that relapse rates between vaccinated and unvaccinated MS patients are virtually indistinguishable .…”

Section: Covid-19 Vaccinementioning

confidence: 94%

Vaccination of multiple sclerosis patients during the COVID-19 era: Novel insights into vaccine safety and immunogenicity

Kim

Haag

Nguyen

et al. 2022

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

“…The intensity and frequency of which were higher after the second dose [15]. Generally vomiting [16], local pain, joint pain, fatigue, fever, arthralgia, myalgia, headache and palpitation were reported as the vaccination side effects [11,17].…”

Section: What Symptoms Can Be Predicted After Receiving Covid-19 Vacc...mentioning

confidence: 99%

“…196 of whom had received Pfizer vaccine and 506 individuals had administrated AstraZeneca vaccine, [10] reported at least one side effect after the injection such as pain at injection site, fever and myalgia. As a result, symptoms after vaccination are natural phenomena and indicate the body immunization response to vaccine [11]. In another study a group consisted of 19 individuals (mean age 28.8) who had received both vaccine doses were surveyed via a portable device with the aim of characterizing physiologic changes of body [12].…”

Section: What Symptoms Can Be Predicted After Receiving Covid-19 Vacc...mentioning

confidence: 99%

Evaluation of vaccines effective against coronavirus

Abadi

Rahmanian

Asadsangabi

et al. 2022

clin. med. & helt. res. jour.

View full text Add to dashboard Cite

Given the COVID-19 virus epidemic and vaccination increment all around the world, after surveying the vaccination side effects it was clarified that 72.6% of individuals reported at least one symptom after the first and second injection of Pfizer-BioNTech vaccine which pain at injection site, fever and myalgia/arthralgia were most common among these symptoms. Furthermore, most common severe side effects like fever > 39 °C were perceived more after the second dose of vaccine. In the study of identifying body’s physiologic changed, heart rate variability (HRV) decreased after the first dose and the second dose without having considerable changes in resting heart rate (RHR) and respiratory rate (RR) and the duration of sleep also declined up to 4 days of both vaccination doses. Plus, Local and systemic reactogenicity were more intense after the second dose. Following the COVID-19 vaccination, various allergic reactions also started to promote all around the countries, a questionnaire was adjusted in Toronto-Canada and 65 patients had PEG-ASNase allergy. Rapid reactions like anaphylaxis occur following the first dose of Pfizer mRNA COVID-19 vaccine. In a study consisted of 175 individuals, 21 of them were afflicted with anaphylaxis and a number of 83 individuals experienced non-anaphylaxis allergic reactions but still further studies are required in order to identify the relation between anaphylaxis and COVID-19 vaccines. Disease background is an outstanding factor to intensify COVID-19 infection. In a research, a 40-year old woman who had experienced left peripheral facial nerve palsy 4 years ago and in another research 8 adolescents who visited Nicklaus Children’s Hospital with perimyocarditis within 4 days of receiving the second dose of BNT162b2 vaccine, were investigated in this context. In terms of gender and age relation, a study was carried out on German residents of Bavaria between Jan 9 to Apr 11, 2021 and, it was clarified that both doses of the BioNTech-Pfizer’s BNT162b2 are highly effective against the infection and adverse events of COVID-19 virus in elder people and according to another report, 82% of individuals experienced at least one symptom Following the first dose of Comirnaty vaccine which was more common in women under the age 55 (64%). In a study which was carried out among the workers of Mazandaran University of Medical Sciences in order to identify the side effects of the Sputnik V vaccine, a number of 3236 individuals in the 19-78 age range with the mean age of 38 years old submitted their report. According to a research which was conducted in Bavaria, Germany, the mortality rate was considerably lower in individuals who had received vaccination in relation to not vaccinated individuals, however, 3 death cases were reported in individuals who suffered from comorbidities after receiving the Sputnik vaccine which was considered to be irrelevant to vaccination. A research was conducted to evaluate the effectiveness of Robust antibody after the first and second dose in individuals aged between 70 and 90. From 99 individuals who received the first dose of their vaccination after 3 weeks the existence of Robust antibody was proven in 95% of them and from 86 individuals who received their vaccine’s second dose after 3 weeks, all of them showed a positive result in the test. Furthermore, in another study from 75% of old individuals who were vaccinated at least once, the first dose led into COVID-19 infection decrease and had an effectiveness of 52% in clinical experiments. According to another report, the antibody was observed in 92% of individuals 21 days after the first dose and also in 97% of them 21 days after the second dose it was concluded that Symptoms following vaccination are not unusual and they occur because of body’s immune system response.

show abstract

Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine

Cited by 23 publications

References 9 publications

New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure

New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure

Vaccination of multiple sclerosis patients during the COVID-19 era: Novel insights into vaccine safety and immunogenicity

Evaluation of vaccines effective against coronavirus

Contact Info

Product

Resources

About